The purpose of this work was to demonstrate proof-of-concept for a stable sustained release dosage form containing phenylephrine hydrochloride (PE HCI) using Capsugel's Solid Lipid Pellets (SLP) technology.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest CHI content
Latest briefing from the Knowledge Center